Skip to main content

Table 4 Univariate analyses of factors affecting household transmission of influenza infection

From: Efficacy of baloxavir marboxil on household transmission of influenza infection

Variables With household transmission (n = 51) Without household transmission (n = 367) Odds ratio (95% CI) P value
Age of household patients (years), n (%)
 0–6 12 (23.5) 35 (9.5) 2.92 (1.40–6.09) < 0.01
 7–19 7 (13.7) 62 (16.9) 0.93 (0.42–2.08) 0.87
 20–64 27 (52.9) 216 (58.8) 0.77 (0.42–1.38) 0.38
 ≥ 65 5 (9.8) 54 (14.7) 0.63 (0.24–1.66) 0.34
Age of index patients (years), n (%)
 0–6 7 (13.7) 60 (16.3) 0.81 (0.35–1.89) 0.63
 7–19 14 (27.4) 114 (31.1) 0.84 (0.44–1.61) 0.60
 20–64 23 (45.1) 144 (39.2) 1.29 (0.71–2.32) 0.40
 ≥ 65 7 (13.7) 49 (13.4) 1.03 (0.44–2.42) 0.94
Household size, n (%)
 ≤ 3 15 (29.4) 101 (27.5) 1.10 (0.58–2.09) 0.78
 4 22 (43.1) 141 (38.4) 1.22 (0.67–2.20) 0.52
 ≥ 5 14 (27.4) 125 (34.1) 0.73 (0.38–1.41) 0.35
Influenza vaccination in the same eason in household patients, n (%) 18 (35.3) 117 (31.9) 1.17 (0.63–2.16) 0.63
Index patients with baloxavir treatment, n (%) 10 (19.6) 108 (29.4) 0.59 (0.28–1.21) 0.14
Respiratory tract symptoms in index patients, n (%) 23 (45.1) 132 (36.0) 1.46 (0.81–2.64) 0.31
  1. CI Confidence interval